Toronto-Ontario-based Ventripoint Diagnostics is rolling out broader hospital access to its VMS+ AI-assisted cardiac imaging platform through a subscription-based model.
VMS+ 4.0 uses AI to generate 3D models and quantitative measurements of all four heart chambers from standard echocardiography images, according to Ventripoint. The platform received U.S. Food and Drug Administration (FDA) 510(k) clearance in 2025 and holds regulatory approvals in Canada, the European Union, and the U.K.
The commercial push follows Ventripoint's July selection for the Intelligence Reconstruction of Echocardiography Study (AIRES) led by The Royal Wolverhampton NHS Trust in the U.K. The NHS describes AIRES as the world's first study evaluating AI-enabled echocardiography specifically in oncology patients, the company said.
